ClinicalTrials.Veeva

Menu

Evaluation of the Effects of Duloxetine on Norepinephrine

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Major Depressive Disorder

Treatments

Drug: Escitalopram
Drug: Duloxetine
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00414323
F1J-MC-HMEU
9547

Details and patient eligibility

About

The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal fluid.

Enrollment

35 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Healthy subjects between the ages of 18-65 years are nonsmokers or are willing to refrain from smoking and are not taking concomitant medications which may inhibit or induce CYP1A2 or CYPD6 or is an MAOI.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems